Journal of Clinical Oncology, Vol 6, 62-66, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Cisplatin in the treatment of recurrent childhood primary brain tumors

RW Walker and JC Allen
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Thirty-three patients were treated with intravenous (IV) cisplatin (CPDD) of whom 32 were considered evaluable. There were 14 medulloblastomas, five primitive neuroectodermal tumors (PNET), nine gliomas, three ependymomas, and one germ cell tumor. The overall response rate was 13 of 32 (41%). Eleven responses (five complete [CR], five partial [PR], one mixed [MR]) were noted in the patients with medulloblastoma. The response rate within this group was 79%. Toxicity was tolerable, although it precluded further therapy in five patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. A Walker, J. A G Punt, and M. Sokal Clinical management of brain stem glioma Arch. Dis. Child., June 1, 1999; 80(6): 558 - 564. [Full Text]

				R. J. Packer and J. L. Finlay Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors Oncologist, December 1, 1996; 1(6): 381 - 393. [Abstract] [Full Text] [PDF]

				M. C. Chamberlain, D. Barba, P. Kormanik, A. M. Berson, W. M. Saunders, and M. C. Shea Concurrent Cisplatin Therapy and Iodine 125 Brachytherapy for Recurrent Malignant Brain Tumors Arch Neurol, February 1, 1995; 52(2): 162 - 167. [Abstract] [PDF]

				B. L. Maria, K. Rehder, T. A. Eskin, L. M. Hamed, E. B. Fennell, R. G. Quisling, J. P. Mickle, R. B. Marcus Jr, W. E. Drane, N. P. Mendenhall, et al. Topical Review Article: Brainstem Glioma: I. Pathology, Clinical Features, and Therapy J Child Neurol, April 1, 1993; 8(2): 112 - 128. [Abstract] [PDF]